Evidence map›Paper›PMID 25652802›Full record

ArticleBMJ open2015

Loss of GD1-positive Lactobacillus correlates with inflammation in human lungs with COPD.

Marc A Sze, Soraya Utokaparch, W Mark Elliott, James C Hogg, Richard G Hegele

Open access · goldAbstract read
In one paragraph

Article in BMJ open, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. The Beneficial Role of ProbioticFrontiers in immunology · 2022
    Review
  6. Review
  7. Article
  8. Article
  9. The Microbiome and the Respiratory Tract.Annual review of physiology · 2016
    Review
  10. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Marc A SzeDepartments of Medicine and Pathology and Laboratory Medicine, Centre for Heart Lung Innovation, Providence Heart-Lung Institute at St Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada.
Soraya UtokaparchDepartments of Medicine and Pathology and Laboratory Medicine, Centre for Heart Lung Innovation, Providence Heart-Lung Institute at St Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada.
W Mark ElliottDepartments of Medicine and Pathology and Laboratory Medicine, Centre for Heart Lung Innovation, Providence Heart-Lung Institute at St Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada.
James C HoggDepartments of Medicine and Pathology and Laboratory Medicine, Centre for Heart Lung Innovation, Providence Heart-Lung Institute at St Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada.
Richard G HegeleDepartment of Laboratory Medicine and Pathobiology, University of Toronto, Ontario, Canada.
St. Paul's Hospital · CAUniversity of British Columbia · CAUniversity of Toronto · CA

Funding

Peripheral Markers of Phenotypic Heterogeneity in COPDP50HL084948 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SCIURBA, FRANK · 2007 to 2012
$12.8M
Canadian Institutes of Health ResearchNHLBI NIH HHS HL084948NHLBI NIH HHS P50 HL084948
6 · The paper itself

Abstract

objectivesThe present study assesses the relationship between contents of GD1 (glycerol dehydratase)-positive Lactobacillus, presence of Lactobacillus and the inflammatory response measured in host lung tissue in mild to moderate chronic obstructive pulmonary disease (COPD). We hypothesise that there will be a loss of GD1 producing Lactobacillus with increasing severity of COPD and that GD1 has anti-inflammatory properties.

settingSecondary care, 1 participating centre in Vancouver, British Columbia, Canada.

participants74 individuals who donated non-cancerous portions of their lungs or lobes removed as treatment for lung cancer (normal lung function controls (n=28), persons with mild (GOLD 1) (n=21) and moderate (GOLD 2) COPD (n=25)). OUTCOME MEASURES: Primary outcome measure was GD1 positivity within each group and whether or not this impacted quantitative histological measures of lung inflammation. Secondary outcome measures included Lactobacillus presence and quantification, and quantitative histological measurements of inflammation and remodelling in early COPD.

resultsTotal bacterial count (p>0.05) and prevalence of Lactobacillus (p>0.05) did not differ between groups. However, the GD1 gene was detected more frequently in the controls (14%) than in either mild (5%) or moderate (0%) COPD (p<0.05) samples. Macrophage and neutrophil volume fractions (0.012±0.005 (mean±SD) vs 0.026±0.017 and 0.005±0.002 vs 0.015±0.014, respectively) in peripheral lung tissue were reduced in samples positive for the GD1 gene (p<0.0035).

conclusionsA reduction in GD1 positivity is associated with an increased tissue immune inflammatory response in early stage COPD. There is potential for Lactobacillus to be used as a possible therapeutic, however, validation of these results need to be completed before an anti-inflammatory role of Lactobacillus in COPD can be confirmed.

Indexed as

Genes, BacterialAgedBacterial ProteinsBritish ColumbiaFemaleForced Expiratory VolumeHumansHydro-LyasesInflammationLactobacillusLungMacrophagesMaleMiddle AgedNeutrophilsPulmonary Disease, Chronic ObstructiveBacterial Proteinsglycerol dehydrataseHydro-Lyases

Identifiers

PMID25652802
PMCPMC4322209
OpenAlexW2110342877

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.